$89.26
-0.47 (-0.52%)
USD · as of 2026-08-18 · marketstack
Clinical trials
catalyst calendar across sponsors →Studies where MMSI is the lead sponsor, as filed with ClinicalTrials.gov. Completion dates are the sponsor's own projected windows and are revised as a study runs. Active studies first, then completed and stopped — newest readout first within each.
15 interventional · 14 observational · 13 with posted results
Held by 16 tracked-famous managers (MAVERICK CAPITAL LTD, CITADEL ADVISORS LLC, AQR CAPITAL MANAGEMENT LLC, TWO SIGMA INVESTMENTS, LP, MARSHALL WACE, LLP, +11 more) · FINRA short interest 3.7 days to cover (settled 2026-07-31) · government filings 180d: 0 congress / 1 executive
| Study | Phase | Status | Interventions | Conditions | Enrollment | Primary completion | Readout in | Updated |
|---|---|---|---|---|---|---|---|---|
| WRAP North AmericaNCT06807099observationalProportion of subjects with Target Lesion Primary Patency (TLPP) (Primary Effectiveness Endpoint) | — | Recruiting | Device: Merit WRAPSODY® Cell Impermeable Endoprosthesis (WRAPSODY CIE) | Venous Stenosis, Venous Occlusion | 250 | Dec 2027 | ≤ 499 d | 2026-06-17 |
| PReSeRVE-HD: Observational Study of the Merit HeRO® Graft and Super HeRO® in Patients on HemodialysisNCT06422871observationalComposite Endpoint | — | Recruiting | Device: HeRO® Graft System or Super HeRO® System | End Stage Renal Disease, Hemodialysis Access Failure | 100 | 2027-06-28 | in 313 d | 2026-06-01 |
| US Post-Market Surveillance Study of the Surfacer SystemNCT05050799observationalCentral Venous Access operational | — | Recruiting | Device: Central Venous Access | Venous Disease | 30 | 2026-12-15 | in 118 d | 2026-06-01 |
| PREEMIE: Study for Treatment of PDA in Premature InfantsNCT06587282Safety EndpointOpen-label · Treatment | Not applicable | Active, not recruiting | Device: Bloom Micro Occluder System | Patent Ductus Arteriosus (PDA) | 55 | Aug 2026 | ≤ 12 d | 2026-05-15 |
| Bearing nsPVA Embolization for Uterine Artery Embolization (BETTER-UAE)NCT06153667observationalPrimary Safety | — | Recruiting | Device: Bearing nsPVA | Uterine Fibroid | 100 | Jun 2026 | — | 2026-05-29 |
| C2 CryoBalloon™ 180 Ablation System Dose De-escalation Study.NCT03311451Efficacy: Dose responseOpen-label · Treatment | Not applicable | Active, not recruiting | Device: C2 CryoBalloon 180° Ablation System | Barrett Esophagus | 62 | 2026-06-18 | — | 2026-05-22 |
| GAE Using Embosphere Microspheres vs Corticosteroid Injections for Treatment of Symptomatic Knee OA (MOTION)NCT05818150Primary Efficacy EndpointRandomized · Open-label · Treatment | Not applicable | Active, not recruiting | Device: Embosphere Microspheres · Drug: Corticosteroid injection | Knee Osteoarthritis | 264 | Apr 2026 | — | 2025-10-24 |
| Merit WRAPSODY™ Endoprosthesis for Treatment of Stenosis or Occlusion (WRAP)NCT05062291observationalProportion of subjects with Target Lesion Primary Patency (TLPP) (Primary Effectiveness Endpoint) | — | Active, not recruiting | Device: Merit WRAPSODY Endovascular Stent Graft | Venous Stenosis, Venous Occlusion | 500 | 2026-04-15 | — | 2025-12-10 |
| EmboCube Gelatin Embolization to Control Bleeding or HemorrhagingNCT05307783results2025-01-22observationalNumber of Participants With Clinical Success: Cessation of Bleeding up to 24 HoursStudy Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Device: EmboCube Embolization Gelatin | Hemorrhage, Bleeding Hemorrhage | 101 | 2024-03-15actual | — | 2025-01-22 |
| The Merit WRAPSODY AV Access Efficacy Study (WAVE)NCT04540302results2026-06-10Subjects Without Any Localized or Systemic Safety Events (Primary Safety Endpoint)Randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Merit WRAPSODY Endovascular Stent Graft, PTA | Venous Stenosis, Venous Occlusion | 357 | 2024-02-22actual | — | 2026-06-10 |
| Streamlined Localization Using SCOUT® at Biopsy (STREAMLoc )NCT04815291results2024-05-21Number of Participants Invasive VisitsOpen-label · TreatmentStudy Protocol ↗ · Statistical Analysis Plan ↗ | Not applicable | Terminatedsponsor's stated reason: Sponsor decision. | Device: Receives SCOUT at biopsy | Breast Cancer | 93 | 2024-01-15actual | — | 2024-05-21 |
| The Merit WRAPSODY Central Feasibility StudyNCT04541576Proportion of subjects without any localized or systemic safety events (Primary Safety EndpointOpen-label · Treatment | Not applicable | Withdrawnsponsor's stated reason: FDA Approval | Device: Merit WRAPSODY Endovascular Stent Graft | Venous Stenosis, Venous Occlusion | 0 | Jul 2022 | — | 2021-04-20 |
| HepaSphere™ Microspheres Prospective RegistryNCT04866290results2022-10-12observationalOverall SurvivalStudy Protocol ↗ · Statistical Analysis Plan ↗ | — | Completed | Device: HepaSphere Microspheres | Metastatic Colorectal Cancer | 105 | Jun 2021actual | — | 2023-04-03 |
| HepaSphere/Quadrasphere Microspheres for Delivery of Doxorubicin for the Treatment of Hepatocellular CancerNCT01387932results2021-11-30Median Overall SurvivalRandomized · Double-masked · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Phase 3 | Terminatedsponsor's stated reason: The clinical study was terminated due to the inability to meet target enrollment. | Device: HepaSphere/QuadraSphere Microspheres · Procedure: PVA, lipiodol, doxorubicin | Hepatocellular Carcinoma | 235 | Feb 2021actual | — | 2021-11-30 |
| The Merit WRAPSODY™ Endovascular Stent Graft for Treatment of Iliac Artery Occlusive DiseaseNCT03994185Safety endpoint of subjects free from specified adverse eventsOpen-label · Treatment | Not applicable | Withdrawnsponsor's stated reason: Study was withdrawn by the Sponsor prior to enrollment | Device: Placement of WRAPSODY stent graft | Stenosis of Artery, Peripheral Arterial Disease, Iliac Artery Disease, Iliac Artery Occlusion | 0 | Sep 2020 | — | 2020-04-24 |
| The Merit WRAPSODY™ Endovascular Stent GraftNCT03644017results2021-07-21Number of Participants Without Any Localized or Systemic Safety Events Through 30 DaysOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: WRAPSODY Stent Graft Placement | Venous Stenosis, Venous Occlusion | 46 | 2020-02-25actual | — | 2022-01-21 |
| Embosphere® PROstate Post Market StudyNCT03527589results2023-12-18observationalLong-term Effectiveness of Prostatic Artery Embolization (PAE) With Embosphere Microspheres as Assessed by the International Prostate Symptom Score (IPSS).Study Protocol and Statistical Analysis Plan ↗ | — | Completed | Device: Prostate artery embolization | Benign Prostatic Hyperplasia, Lower Urinary Tract Symptoms | 499 | 2020-01-21actual | — | 2023-12-18 |
| Evaluation of the Surfacer System Approach to Central Venous AccessNCT03209050results2021-08-12Number of Participants With Safe Insertion and Patency of Central Venous Access CatheterOpen-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Completed | Device: Central Venous Access Placement | Venous Occlusion | 30 | 2019-05-24actual | — | 2023-05-30 |
| Data Collection Registry of the HeRO Graft for End Stage Renal Disease Patients Receiving HemodialysisNCT02164175observationalMortality | — | Withdrawnsponsor's stated reason: Company acquired and trial was not pursued | Device: HeRO Graft implant for dialysis access | End Stage Renal Failure on Dialysis | 0 | Dec 2018 | — | 2021-05-10 |
| Surfacer System to Facilitate Access in Venous OcclusionsNCT02875899observationalAbsence of all acute safety and device related serious adverse event recorded on case report forms | — | Completed | — | Chronic Venous Thrombosis, Venous Thrombosis Upper Extremity, Venous Thrombosis Upper Extremity Superficial Veins | 30 | 2018-09-20actual | — | 2024-01-26 |
| Prostate Artery Embolization With Embosphere Microspheres Compared to TURP for Benign Prostatic HyperplasiaNCT01789840results2021-11-11International Prostate Symptom Score (IPSS) - Total Score at 12 MonthsNon-randomized · Open-label · TreatmentStudy Protocol and Statistical Analysis Plan ↗ | Not applicable | Terminatedsponsor's stated reason: 510(K) Approval Gained for Product | Device: Embosphere Microspheres · Procedure: TURP | Benign Prostatic Hyperplasia | 59 | Jun 2017actual | — | 2021-11-11 |
| The STAR™ Tumor Ablation RegistryNCT02419703observationalPain relief (Numerical Rating Pain Scale), post t-RFA | — | Terminatedsponsor's stated reason: Difficulty Enrolling | Device: STAR™ Tumor Ablation System | Metastatic Lesions in Vertebral Bodies | 65 | 2017-03-20actual | — | 2017-04-12 |
| EndoMAXX Endoluminal Valve Technology (EVT) Compared to EndoMAXXNCT02159898results2018-06-07Mellow and Pinkas Dysphagia Score at Baseline and 2 Weeks Following the TreatmentRandomized · Single-masked · Treatment | Not applicable | Completed | Device: EndoMAXX Endoluminal Valve Technology (EVT), EndoMAXX | Malignant Esophageal Strictures | 60 | Oct 2016actual | — | 2018-06-07 |
| Evaluation of t-RFA and RF-TVA Prior to/Following Radiation Therapy to Treat Painful Metastatic Vertebral Body Tumor(s)NCT02225223results2021-07-21Mean Change From Baseline in Brief Pain Inventory Q3 Worst Pain Score at 6 WeeksNon-randomized · Open-label · Treatment | Not applicable | Terminatedsponsor's stated reason: Difficulty Enrolling | Device: STAR™ Tumor Ablation System, StabiliT® Vertebral Augmentation System | Metastatic Lesions in Vertebral Bodies | 35 | Oct 2016actual | — | 2021-08-11 |
| Post Marketing Surveillance of the CentrosFLO™ Tunneled IJ CatheterNCT02349308observationalPrimary Endpoint: Stability of hydraulic resistance measured as normalized arterial pressure in mmHg/mL/min by dialysis flow meter weekly for up to six months | — | Completed | Device: CentrosFLO Long Term Hemodialysis Catheter | Pain; Dialysis Catheter | 10 | Jul 2015actual | — | 2015-09-03 |
| HeRO Graft Compared to Permanent Catheters for End Stage Renal Disease (ESRD) Patients Receiving HemodialysisNCT01343251results2016-03-14observationalMortality | — | Completed | — | End Stage Renal Disease (ESRD) | 33 | Dec 2013actual | — | 2017-09-08 |
| HeRO Vascular Access Device Post Market Procedural Survey ProtocolNCT00889291observationalDevice placement success | — | Completed | — | End Stage Renal Disease | 77 | Jan 2009actual | — | 2017-08-08 |
| Hemodialysis Reliable Outflow (HeRO) Vascular Access Patency StudyNCT00890045results2021-06-09Percentage of Patients With Primary PatencyRandomized · Open-label · Treatment | Not applicable | Completed | Device: HeRO Vascular Access Device, Conventional ePTFE hemodialysis graft | Renal Failure Chronic Requiring Hemodialysis | 72 | Mar 2008actual | — | 2024-01-29 |
| HeRO Vascular Access Device Bacteremia StudyNCT00889564HeRO superiority in device and implant procedure-related bacteremia compared to historical tunneled dialysis catheter literature controlNon-randomized · Open-label · Treatment | Not applicable | Completed | Device: HeRO Vascular Access Device | Hemodialysis | 38 | Mar 2007actual | — | 2017-08-08 |
Primary completion is the date the sponsor filed with the registry — their own projection, revised whenever they revise it, unless the row is marked actual.
Source: ClinicalTrials.gov, retrieved 2026-08-19